Summary
Edwards Lifesciences Corporation (EW) reported its first-quarter 2012 financial results, demonstrating solid revenue growth driven significantly by its Transcatheter Heart Valves segment. Net sales increased by 13.5% year-over-year, reaching $459.2 million. This growth was predominantly fueled by the U.S. launch of the Edwards SAPIEN transcatheter heart valve and continued international expansion of the Edwards SAPIEN XT. The company also saw modest growth in its Surgical Heart Valve Therapy and Critical Care segments. Profitability showed improvement, with gross profit margin increasing by 1.2 percentage points to 72.3%, attributed to a more favorable product mix, particularly from higher-margin transcatheter valves. However, Selling, General, and Administrative (SG&A) expenses and Research & Development (R&D) expenses also increased, reflecting investments in sales and marketing for the transcatheter valve program and ongoing product development. Despite these investments, net income saw a slight increase to $65.1 million from $63.9 million in the prior year's comparable quarter, with diluted earnings per share improving to $0.55.
Financial Highlights
43 data points| Revenue | $459.20M |
| Cost of Revenue | $127.30M |
| Gross Profit | $331.90M |
| R&D Expenses | $68.60M |
| SG&A Expenses | $177.20M |
| Net Income | $65.10M |
| EPS (Basic) | $0.10 |
| EPS (Diluted) | $0.09 |
| Shares Outstanding (Basic) | 684.00M |
| Shares Outstanding (Diluted) | 708.00M |
Key Highlights
- 1Net sales grew 13.5% to $459.2 million, driven by strong performance in Transcatheter Heart Valves.
- 2Transcatheter Heart Valves segment sales surged 67.2% to $121.5 million, largely due to the U.S. launch of the Edwards SAPIEN valve.
- 3Gross profit margin improved to 72.3% from 71.1%, benefiting from a richer product mix, especially transcatheter valves.
- 4Increased investment in SG&A and R&D, up by $26.9 million and $9.6 million respectively, to support transcatheter valve commercialization and product development.
- 5Net income rose to $65.1 million ($0.55 diluted EPS) from $63.9 million ($0.53 diluted EPS) in the prior year's quarter.
- 6The company entered into an Accelerated Share Repurchase (ASR) agreement for $54.0 million, demonstrating a commitment to returning capital to shareholders.
- 7The company is actively involved in several patent litigations, primarily with Medtronic, related to heart valve technologies, with outcomes pending appeal or reexamination.